As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.
11 Analysts have issued a Biodesix Inc forecast:
11 Analysts have issued a Biodesix Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 80 80 |
22%
22%
|
|
| Gross Profit | 64 64 |
26%
26%
|
|
| EBITDA | -27 -27 |
9%
9%
|
|
| EBIT (Operating Income) EBIT | -32 -32 |
6%
6%
|
|
| Net Profit | -40 -40 |
10%
10%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
| Head office | United States |
| CEO | Scott Hutton |
| Employees | 273 |
| Founded | 2005 |
| Website | www.biodesix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


